SEC Form 4 · accession 0001209191-15-071276

Anacor Pharmaceuticals, Inc. · ANAC

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP and Chief Medical Officer

Period of report

Sep 15, 2015

Accepted (ET)

Sep 17, 2015 · 9:45 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001411158

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Sep 15, 2015	M	14,000	$5.59	A	42,744	D
Common Stock^F3	Sep 15, 2015	S	1,500	$138.9987	D	41,244	D
Common Stock^F4	Sep 15, 2015	S	11,199	$139.8479	D	30,045	D
Common Stock^F5	Sep 15, 2015	S	1,301	$140.6957	D	28,744	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F6	$5.59	Sep 15, 2015	M	14,000	D	—	Mar 13, 2022	Common Stock	14,000	41,661	D

F1Includes 588 shares purchased on July 31, 2015 pursuant to the Issuer's ESPP.
F2This sale was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
F3The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $138.44 to $139.43, inclusive.
F4The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $139.46 to $140.45, inclusive.
F5The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $140.50 to $140.90, inclusive.
F61/4 of the shares subject to the option shall vest and become exercisable on the one-year anniversary of the Vesting Commencement Date, which is January 1, 2012, and 1/48 of the shares subject to the option shall vest and become exercisable each month thereafter.